Your browser doesn't support javascript.
loading
Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer.
Arai, Jun; Otoyama, Yumi; Fujita, Ken-Ichi; Goto, Kaku; Tojo, Masayuki; Katagiri, Atsushi; Nozawa, Hisako; Kubota, Yutaro; Takahashi, Takehiro; Ishida, Hiroo; Tsunoda, Takuya; Matsumoto, Natsumi; Ogawa, Keita; Nakagawa, Ryo; Muroyama, Ryosuke; Kato, Naoya; Yoshida, Hitoshi.
Afiliación
  • Arai J; Division of Gastroenterology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, Japan. araiguma10@med.showa-u.ac.jp.
  • Otoyama Y; Division of Gastroenterology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, Japan.
  • Fujita KI; Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan.
  • Goto K; Institut de Recherche Sur Les Maladies Virales Et Hépatiques, INSERM, Strasbourg, France.
  • Tojo M; Division of Gastroenterology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, Japan.
  • Katagiri A; Division of Gastroenterology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, Japan.
  • Nozawa H; Division of Gastroenterology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, Japan.
  • Kubota Y; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
  • Takahashi T; Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Japan.
  • Ishida H; Division of Internal Medicine, Department of Medicine, Showa University Hokubu Hospital, Yokohama, Japan.
  • Tsunoda T; Division of Medical Oncology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
  • Matsumoto N; Division of Cancer Genome and Pharmacotherapy, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan.
  • Ogawa K; Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Nakagawa R; Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Muroyama R; Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Kato N; Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Yoshida H; Division of Gastroenterology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, Japan.
BMC Cancer ; 22(1): 428, 2022 Apr 20.
Article en En | MEDLINE | ID: mdl-35443621
ABSTRACT

BACKGROUND:

To evaluate the effect of regorafenib on soluble MHC class I polypeptide-related sequence A (MICA) (sMICA) level in vitro. In addition, we clinically examined whether its plasma levels were associated with regorafenib activity in terms of progression-free survival (PFS) in patients with CRC.

METHODS:

Human CRC cell line HCT116 and HT29 cells were treated with regorafenib and its pharmacologically active metabolites, M2 or M5 at the same concentrations as those in sera of patients. We also examined the sMICA levels and the area under the plasma concentration-time curve of regorafenib, M2 and M5.

RESULTS:

Regorafenib, M2, and M5 significantly suppressed shedding of MICA in human CRC cells without toxicity. This resulted in the reduced production of sMICA. In the clinical examination, patients with CRC who showed long median PFS (3.7 months) had significantly lower sMICA levels than those with shorter median PFS (1.2 months) (p = 0.045).

CONCLUSIONS:

MICA is an attractive agent for manipulating the immunological control of CRC and baseline sMICA levels could be a predictive biomarker for the efficacy of regorafenib treatment.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Antígenos de Histocompatibilidad Clase I Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Antígenos de Histocompatibilidad Clase I Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Japón